1BT.F · Enlivex Therapeutics Ltd

-

Please sign in to comment on 1BT.F

1 Comment

Admin

4 years ago

Enlivex Therapeutics Ltd is currently in a long term downtrend where the price is trading 30.5% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Enlivex Therapeutics Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 11.1% to $-2M since the same quarter in the previous year.

Finally, its free cash flow fell by 30.4% to $-3M since the same quarter in the previous year.

Based on the above factors, Enlivex Therapeutics Ltd gets an overall score of 2/5.

Sector	Healthcare
Industry	Biotechnology
Exchange	F
CurrencyCode	EUR
ISIN	IL0011319527

Beta	0.84
Market Cap	18M
PE Ratio	None
Target Price	None
Dividend Yield	None

ABOUT

Enlivex Therapeutics Ltd

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

1BT.F · Enlivex Therapeutics Ltd

-

Enlivex Therapeutics Ltd

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Enlivex Therapeutics Ltd using a moving average strategy